Meeting
2021 ASCO Quality Care Symposium
Real-world treatment patterns of metastatic non-small cell lung cancer (mNSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
Authors
Rahul Shenolikar
AstraZeneca Pharmaceuticals LP, Gaithersburg, MD
Rahul Shenolikar, Sizhu Liu, Jenny Tse, Yao Cao, Aimee Near
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Patient Experience; Quality, Safety, and Implementation Science; Technology and Innovation in Quality of Care
Track
Technology and Innovation in Quality of Care,Patient Experience,Quality, Safety, and Implementation Science,Cost, Value, and Policy,Health Care Access, Equity, and Disparities
Sub Track
Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 28; abstr 289)
DOI
10.1200/JCO.2020.39.28_suppl.289
Abstract #
289
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu
Poster
2023 ASCO Annual Meeting
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
First Author: Min Hee Hong
Poster
2023 ASCO Annual Meeting
Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.
First Author: Xiuning Le
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura